<?xml version="1.0" encoding="UTF-8"?>
<p>American heart association/American stroke association has proposed guidelines in the management of stroke patients during this pandemic insisting the judicious use of emergency services during this period, strictly following the suggested protocol.[
 <xref rid="ref28" ref-type="bibr">28</xref>] National multiple sclerosis society also has made recommendations regarding the initiation/continuation/modifications of disease modifying therapies in multiple sclerosis patients during the pandemic. Immunomodulators that do not increase the risk of infection include glatiramer acetate, interferons and natalizumab. Immunomodulators that increase the risk of infection include dimethyl fumarate, fingolimod, siponimod and teriflunomide. Immunosuppressants increasing the risk of infection include alemtuzumab, ocrelizumab, rituximab, mitoxantrone and cladribine.[
 <xref rid="ref29" ref-type="bibr">29</xref>]
</p>
